Are Charles River’s New Advanced Therapy Deals Quietly Rewriting Its Drug-Development Moat Story (CRL)?

Charles River Laboratories (CRL) recently announced collaborations with Locus Cell and Therna Biosciences, deepening its involvement in advanced therapies like cell, gene, and RNA platforms. These partnerships could strengthen CRL’s position in complex drug development, particularly in ultra-rare diseases, offering higher-value testing opportunities but also increasing exposure to project delays. While these deals support the long-term advanced therapies narrative, they don’t immediately resolve near-term pressures of flat revenue guidance and funding constraints, and rising non-animal methods could reshape CRL’s core business.